ST
Synapse TeamOct 21
Survodutide is a glucagon/GLP-1 receptor dual agonist. If SYNCHRONIZE-CVOT shows fewer cardiovascular events in obesity, where does it sit next to semaglutide and tirzepatide in your practice?
Key result
SYNCHRONIZE-CVOT trial evaluates survodutide for cardiovascular outcomes in patients with obesity, with results pending.
Why the trial?
Does survodutide improve cardiovascular outcomes in patients with obesity?
Does survodutide improve cardiovascular outcomes in patients with obesity?
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward SYNCHRONIZE-CVOT's result, from named public quotes (n=0). As of Oct 22, 2026.
Survodutide and cardiovascular outcomes in obesity: results from the SYNCHRONIZE-CVOT trial
Survodutide and cardiovascular outcomes in obesity: results from the SYNCHRONIZE-CVOT trial. Session: LBS.05. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
Hussain et al. (2026) studied this question. Survodutide is being evaluated for its effects on cardiovascular outcomes in patients with obesity in the SYNCHRONIZE-CVOT trial, with clinical results currently pending.